U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors | Region

PRINCETON, N.J.--(BUSINESS WIRE)--Feb 14, 2024--

Related Keywords

Joseph Fiore ,Bristol Myers Squibb ,Linkedin ,Bristol Myers Squibb Company ,Drug Administration ,Twitter ,Instagram ,Facebook ,Exchange Commission ,Youtube ,Myers Squibb ,New Drug Application ,Priority Review ,Prescription Drug User Fee Act ,Bristol Myers ,Point Therapeutics ,Response Evaluation Criteria ,Solid Tumors ,Blinded Independent Central Review ,Positive Solid ,Better Future ,Breakthrough Therapy Designations ,Orphan Drug ,Lung Disease ,Creatine Phosphokinase ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Business Wire ,Region ,